Freak Of The Week !!

[rickotto1]

Found this on another board regarding CLRB today...makes a lot of sense to me.....and i said similar about a potential "revaluing" of CLRB based on this news...12 million market cap is chump change ..absolute chump change if big pharma/biotech company wants or needs to own this technology


Possible buyout???

Forget possible future dilution, just looking at companies intellectual property and patents (over 28 issued and pending) for oncology delivery technology and orphan drug candidates, CLRB is a prime candidate for a buyout from big pharma companies.

http://files.shareholder.com/downloads/AMDA-2J5XQ5/2095683252x0x858018/9306EF62-5DF0-43FC-A5D4-94AA08E7E7A7/CLRB_Corporate_Presentation-1-11-16_F.pdf

“We are convinced that Cellectar’s proprietary technology will provide our cytotoxic molecules with
tissue specificity and enhanced safety which are typically lacking with untargeted agents.”
- Laurent Audoly, Head of R&D of Pierre Fabre Pharmaceuticals (Dec., 2015) p.22 from PDF presentation.

Also see page 23 for upcoming company events in Q2 2016, so not a good time to short CLRB or please do so that we can see a nice sizable squeeze when news comes out, LOL!

http://www.nasdaq.com/symbol/clrb

NASDAQ shows market cap. of approx. $13.2 million / $3.45 share price, so common stock outstanding is approx 3.8 million as of last Friday.

So what is this company's intellectual property and orphan drugs really worth with to big pharma? Worst $150-300 million and 500-800 million at best? This is chump change to the big players.

You do the math... Less